Načítá se...
Gefitinib Plus Bevacizumab vs. Gefitinib Alone for EGFR Mutant Non-squamous Non-small Cell Lung Cancer
Background/Aim: A phase II trial was conducted to assess the efficacy and safety of gefitinib plus bevacizumab for EGFR mutation-positive non-small cell lung cancer (NSCLC). Patients and Methods: Patients were randomly assigned to receive either gefitinib at 250 mg/day alone or with bevacizumab at 1...
Uloženo v:
| Vydáno v: | In Vivo |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
International Institute of Anticancer Research
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6506320/ https://ncbi.nlm.nih.gov/pubmed/30804129 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.11498 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|